• info@heparegenix.com
  • +49 (0)7071 7912810
  • Sitemap
  • Site Notice
  • Privacy Policy
HepaRegeniX GmbH
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • News
  • Contact
Search
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • News
  • Contact

HepaRegeniX startet Phase-1-Studie am Menschen mit dem MKK4‑Inhibitor HRX-0215

p3889712021-12-29T10:44:48+01:00

HRX-0215 ist die erste Substanz in klinischer Testung aus der firmeneigenen niedermolekularen Wirkstoffforschungsplattform.

08/10/2021
By p3889712021, PressemitteilungComments Off
Read more...

HepaRegeniX erreicht Meilenstein mit dem Nachweis von Sicherheit und Wirksamkeit der MKK4-Inhibition im Modell für fortgeschrittene chronische Lebererkrankungen

p3889712021-12-29T11:05:40+01:00

Neue präklinische Daten zeigen vorteilhafte therapeutische Effekte bei mit nicht-alkoholischer Steatohepatitis (NASH) assoziiertem Leberzell-Karzinom (HCC).

12/03/2020
By p3889712020, PressemitteilungComments Off
Read more...

HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model

p3889712021-12-29T11:07:01+01:00

New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.

12/03/2020
By p3889712020, Press releaseComments Off
Read more...

HepaRegeniX gewinnt Branchenexperten Dr. Markus Weissbach als Senior Clinical Advisor

p3889712021-12-29T11:13:43+01:00

30 Jahre Know-how in der klinischen Entwicklung zur Translation der bisherigen vielversprechenden präklinischen Ergebnisse in die Klinik.

11/18/2020
By p3889712020, PressemitteilungComments Off
Read more...

HepaRegeniX hires industry expert Dr. Markus Weissbach as Senior Clinical Advisor

p3889712021-12-29T11:14:10+01:00

30 years of specialist knowledge in clinical operations to translate encouraging preclinical results into the clinic.

11/18/2020
By p3889712020, Press releaseComments Off
Read more...

HepaRegeniX GmbH to deliver an oral presentation of preclinical results on MKK4 inhibition in liver regeneration at The Liver Meeting® 2020

p3889712021-12-29T11:15:52+01:00

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

11/10/2020
By p3889712020, Press releaseComments Off
Read more...

HepaRegeniX GmbH präsentiert präklinische Daten zur Leberregeneration bei Mkk4-Inhibition auf dem AASLD Liver Meeting® 2020

p3889712021-12-29T11:17:29+01:00

Präklinische Daten zeigen die Wirksamkeit von MKK4-Inhibitoren im Bereich der Leberregeneration sowie experimentellen Modellen aktuer und chronischer Lebererkrankungen...

11/10/2020
By p3889712020, PressemitteilungComments Off
Read more...

HepaRegeniX GmbH gewinnt Industrie-Veteran Dr. David Shapiro als Senior Medical Advisor

p3889712021-12-29T11:20:31+01:00

Präklinische Daten zeigen die Wirksamkeit von MKK4-Inhibitoren im Bereich der Leberregeneration sowie experimentellen Modellen aktuer und chronischer Lebererkrankungen...

10/20/2020
By p3889712020, PressemitteilungComments Off
Read more...

HepaRegeniX GmbH hires industry veteran Dr David Shapiro as Senior Medical Advisor

p3889712021-12-29T11:21:56+01:00

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

10/20/2020
By p3889712020, Press releaseComments Off
Read more...

HepaRegeniX GmbH achieves successful proof of efficacy in acute liver disease models for selected MKK4 inhibitors

p3889712021-12-29T11:27:04+01:00

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

07/07/2020
By p3889712020, Press releaseComments Off
Read more...
  Prev123Next  
Get In Touch
HepaRegeniX GmbH: Logo

HepaRegeniX has successfully discovered and developed several drug candidates to combat multiple liver diseases. The first candidate HRX-0215 has recently entered clinical development.

Get in touch

Phone: +49 (0)7071 7912810
Fax: +49 (0)7071 7912809
E-mail: info@heparegenix.com

Address

HepaRegeniX GmbH
Eisenbahnstraße 63
72072 Tübingen
Germany

© Copyright 2016-2020 HepaRegeniX GmbH. All Rights Reserved.